Bing

SEARCH HISTORY

TEL AVIV: Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo Co. Mylan, which has its primary listing in the United States ...
The Economic Times · 6/24/2015
In late April, Mylan NV rejected the cash-and-stock buyout bid from Teva, saying then that the deal undervalued the company. Both Mylan and Israeli based Teva Pharmaceutical Industries Ltd. are looking to consolidate in an increasingly competitive generic ...
Oklahoma News · 6/8/2015
Should I get rid of Mylan Labs, or hold on? A-You should love this stock. Hold and consider buying more shares of Mylan Laboratories Inc. (around $24 a share, New York Stock Exchange), because it is the class act in the generic drug industry, said Jerry ...
Chicago Tribune · 9/26/1994
In light of the acquisition, Teva said it was withdrawing its $40 billion-plus takeover offer for pharmaceuticals company Mylan N.V. Software turns smartphones ... brought them back this year. Republic stock plunges on possible flight disruptions Republic ...
Financial Express · 12 hours ago
Fiat Chrysler
Mylan's cash-and-stock offer comes at a premium of 24% to the latest closing price for Perrigo shares. Mylan says it delivered a proposal to Perrigo on Monday. Perrigo did not immediately respond to a request for comment on the offer. Mylan said it wants ...
Modern Healthcare · 4/8/2015
Teva has offered to buy Mylan for about $40.1 billion in cash and stock in a deal that would create a powerhouse of generic drug development. Mylan, which reincoporated in the Netherlands, ships products from a center in Greensboro, N.C. PITTSBURGH — …
San Francisco Gate · 7/14/2015
The analysts cited Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly & Co. (NYSE: LLY), Mylan N.V. (NYSE: MYL) and Perrigo Co. PLC (NYSE: PRGO) as stocks that may continue to show sector leadership. This top large cap pharmaceutical stock is …
24/7 Wall ST · 3/23/2015
Mylan NV raised its bid for fellow drug maker Perrigo Co. to $32.7-billion in cash and stock, seeking to close the deal to help stave off a hostile takeover by Teva Pharmaceutical Industries Ltd. Mylan’s offer includes $75 (U.S.) in cash and 2.3 shares ...
Globe and Mail · 4/29/2015
Scooping up a company like Biogen would create a great combination, especially because Biogen's stock has suffered a brutal selloff over the past few days. The move for Allergan's generic-drug business removes the …
MSN · 21 hours ago
stocks
2009 Mylan is, of course, in full spin control mode, pumping out press releases saying that they're not to blame, and so on, as they've watched their stock prices tumble more than 10% since the news came out on Sunday. What Should Thyroid Patients Do?
thyroid.about.com · 7/28/2009

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase